The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
Abstract
Purpose: Imatinib (IM) can safely be discontinued in patients with chronic myeloid leukemia (CML) who have had undetectable minimal residual disease (UMRD) for at least 2 years. We report the final results of the Stop Imatinib (STIM1) study with a long follow-up. Patients and Methods: IM was prospectively discontinued in 100 patients with CML with UMRD sustained for at least 2 years. Molecular recurrence (MR) was defined as positivity of BCR-ABL transcript in a quantitative reverse transcriptase polymerase chain reaction assay confirmed by a second analysis point that indicated an increase of one log in relation to the first analysis point at two successive assessments or loss of major molecular response at one point. Results: The median molecular follow-up after treatment discontinuation was 77 months (range, 9 to 95 months). Sixty-one patients lost UMRD after a median of 2.5 months (range, 1 to 22 months), and one patient died with UMRD at 10 months. Molecular recurrence-free survival was 43% (95% CI, 33% to 52%) at 6 months and 38% (95% CI, 29% to 47%) at 60 months. Treatment was restarted in 57 of 61 patients with MR, and 55 patients achieved a second UMRD with a median time of 4 months (range, 1 to 16 months). None of the patients experienced a CML progression. Analyses of the characteristics of the study population identified that the Sokal risk score and duration of IM treatment were significantly associated with the probability of MR. Conclusion: With a median follow-up of more than 6 years after treatment discontinuation, the STIM1 study demonstrates that IM can safely be discontinued in patients with a sustained deep molecular response with no late MR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationMahon, F.-X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70233-3 · Cited by 1,550
Self-citationHochhaus, A., O'Brien, S. G., Guilhot, F., Druker, B. J., Branford, S., Foroni, L., Goldman, J. M., Müller, M. C., Radich, J. P., Rudoltz, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.38 · Cited by 856
Self-citationHochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P. D., Etienne, G., Dorlhiac-Llacer, P. E., Clark, R. E., et al. (2016) · Leukemia · doi:10.1038/leu.2016.5 · Cited by 839
Self-citationRoss, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Yeung, D. T., Dang, P., Goyne, J. M., Slader, C., Filshie, R. J., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483750 · Cited by 710
Kantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610
Self-citationRousselot, P., Huguet, F., Rea, D., Legros, L., Cayuela, J. M., Maarek, O., Blanchet, O., Marit, G., Gluckman, E., Reiffers, J., et al. (2007) · Blood · doi:10.1182/blood-2006-03-011239 · Cited by 538
Self-citationHughes, T. P., Hochhaus, A., Branford, S., Müller, M. C., Kaeda, J. S., Foroni, L., Druker, B. J., Guilhot, F., Larson, R. A., O'Brien, S. G., et al. (2010) · Blood · doi:10.1182/blood-2010-03-273979 · Cited by 489
Self-citationCortes, J. E., Kim, D.-W., Kantarjian, H. M., Brümmendorf, T. H., Dyagil, I., Griskevicius, L., Malhotra, H., Powell, C., Gogat, K., Countouriotis, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7522 · Cited by 466
Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D.-W., Flinn, I. W., Kurokawa, M., Moiraghi, B., Yu, R., et al. (2012) · Leukemia · doi:10.1038/leu.2012.134 · Cited by 442
Self-citationGambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Self-citationRousselot, P., Charbonnier, A., Cony-Makhoul, P., Agape, P., Nicolini, F. E., Varet, B., Gardembas, M., Etienne, G., Réa, D., Roy, L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5797 · Cited by 416
Self-citationJabbour, E., Kantarjian, H. M., Saglio, G., Steegmann, J. L., Shah, N. P., Boqué, C., Chuah, C., Pavlovsky, C., Mayer, J., Cortes, J., et al. (2014) · Blood · doi:10.1182/blood-2013-06-511592 · Cited by 395
Standardized definitions of molecular response in chronic myeloid leukemia
Cross, N. C. P., White, H. E., Müller, M. C., Saglio, G., & Hochhaus, A. (2012) · Leukemia · doi:10.1038/leu.2012.104 · Cited by 378
Kantarjian, H., O'Brien, S., Jabbour, E., Garcia-Manero, G., Quintas-Cardama, A., Shan, J., Rios, M. B., Ravandi, F., Faderl, S., Kadia, T., et al. (2012) · Blood · doi:10.1182/blood-2011-08-358135 · Cited by 334
Imagawa, J., Tanaka, H., Okada, M., Nakamae, H., Hino, M., Murai, K., Ishida, Y., Kumagai, T., Sato, S., Ohashi, K., et al. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00196-9 · Cited by 306
Hehlmann, R., Müller, M. C., Lauseker, M., Hanfstein, B., Fabarius, A., Schreiber, A., Proetel, U., Pletsch, N., Pfirrmann, M., Haferlach, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.9020 · Cited by 300
Ross, D. M., Branford, S., Seymour, J. F., Schwarer, A. P., Arthur, C., Bartley, P. A., Slader, C., Field, C., Dang, P., Filshie, R. J., et al. (2010) · Leukemia · doi:10.1038/leu.2010.185 · Cited by 268
The concept of treatment-free remission in chronic myeloid leukemia
Saußele, S., Richter, J., Hochhaus, A., & Mahon, F.-X. (2016) · Leukemia · doi:10.1038/leu.2016.115 · Cited by 247
Self-citationAge and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
Mori, S., Vagge, E., le Coutre, P., Abruzzese, E., Martino, B., Pungolino, E., Elena, C., Pierri, I., Assouline, S., D'Emilio, A., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24120 · Cited by 207
Chomel, J.-C., Bonnet, M.-L., Sorel, N., Bertrand, A., Meunier, M.-C., Fichelson, S., Melkus, M., Bennaceur-Griscelli, A., Guilhot, F., & Turhan, A. G. (2011) · Blood · doi:10.1182/blood-2011-02-335497 · Cited by 197
Self-citationLee, S.-E., Choi, S. Y., Song, H.-Y., Kim, S.-H., Choi, M.-Y., Park, J. S., Kim, H.-J., Kim, S.-H., Zang, D. Y., Oh, S., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139899 · Cited by 166
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia
Takahashi, N., Kyo, T., Maeda, Y., Sugihara, T., Usuki, K., Kawaguchi, T., Usui, N., Okamoto, S., Ohe, Y., Ohtake, S., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.056853 · Cited by 147
Richter, J., Söderlund, S., Lübking, A., Dreimane, A., Lotfi, K., Markevärn, B., Själander, A., Saußele, S., Olsson‐Strömberg, U., & Stenke, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.6910 · Cited by 136
Hughes, T. P., Lipton, J. H., Spector, N., Cervantes, F., Pasqüini, R., Clementino, N. C. D., Llacer, P. E. D., Schwarer, A. P., Mahon, F., Réa, D., et al. (2014) · Blood · doi:10.1182/blood-2013-12-544015 · Cited by 99
Self-citationThielen, N., van der Holt, B., Cornelissen, J. J., Verhoef, G. E. G., Gussinklo, T., Biemond, B. J., Daenen, S. M. G. J., Deenik, W., Kooy, R. V. M., Petersen, E. J., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.018 · Cited by 71
Yhim, H., Lee, N., Song, E., Yim, C., Jeon, S. Y., Shin, S.-H., Kim, J., Kim, H. S., Cho, E., & Kwak, J. (2012) · Leukemia Research · doi:10.1016/j.leukres.2012.02.011 · Cited by 60
Lee, S., Choi, S. Y., Bang, J., Kim, S., Jang, E., Byeun, J., Park, J. H., Jeon, H., Oh, Y. J., Kim, H., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23427 · Cited by 56
Legros, L., Rousselot, P. H., Giraudier, S., Tulliez, M., Huguet, F., Nicolini, F. E., & Mahon, F. (2012) · Blood · doi:10.1182/blood-2012-02-408229 · Cited by 25
Self-citation
Cited by
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Cancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
“The first prospective proof of concept for stopping TKI treatment was the Stop Imatinib 1 (STIM1) trial which showed that 38% of the patients maintained a molecular remission after a median follow-up of 77 months [110].”
BackgroundSelf-citationSaussele, S., Richter, J., Guilhot, J., Gruber, F. X., Hjorth-Hansen, H., Almeida, A., Janssen, J. J. W. M., Mayer, J., Koskenvesa, P., Panayiotidis, P., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30192-x · Cited by 618
Self-citation
Metadata
- Authors
- Etienne, G., Guilhot, J., Rea, D., Rigal-Huguet, F., Nicolini, F., Charbonnier, A., Guerci-Bresler, A., Legros, L., Varet, B., Gardembas, M., Dubruille, V., Tulliez, M., Noel, M.-P., Ianotto, J.-C., Villemagne, B., Carré, M., Guilhot, F., Rousselot, P., & Mahon, F.-X.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-01-20
- Volume
- 35
- Issue
- 3
- Pages
- 298-305
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2528188718
- Cited by
- 496
- References
- 29
- FWCI
- 41.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.